Los puntos clave no están disponibles para este artículo en este momento.
We investigated the efficacy and safety of dupilumab in Japanese patients aged ≥6 months to <18 years old with moderate-to-severe atopic dermatitis not adequately controlled with existing therapies.
Ebisawa et al. (Sat,) studied this question.